Environmentally classified pharmaceuticals

Two substances may have the same risk values but different PBT values, but the risk assessment can also be different even if the PBT values are the same. When assessing a medication's environmental impact, consideration should be given to both environmental risk and environmental hazard since bioaccumulation and persistence are not included in the risk assessment.

The Swedish Association of the Pharmaceutical Industry conducted the environmental risk assessment, beginning in 2005.

How to read the table

Last updated: 2010-01-11

« New search


L Antineoplastic and immunomodulating agents

 Substance  Risk  PBT  P  B  T  Volume in DDD  ATC
Antineoplastic agents L01
gemcitabine insigni-
ficant
5 3 0 2 L01B C05
doxorubicin insigni-
ficant
- - - 2
N.B.
L01D B01
etoposide cannot be excl 3
N.B.
3
N.B.
0 0
N.B.
L01C B01
carboplatin cannot be excl 4
N.B.
3
N.B.
0 1
N.B.
L01X A02
oxaliplatin cannot be excl 6
N.B.
3 0 3
N.B.
L01X A03
paclitaxel cannot be excl 6
N.B.
0 3 3
N.B.
L01C D01
cytarabine cannot be excl - - - - L01B C01
epirubucin cannot be excl - - - - L01D B03
mitomycin   6 3 0 3 L01D C03
cisplatin   6
N.B.
3
N.B.
0 3 L01X A01
alemtuzumab none         L01X C04
bevacizumab none         L01X C07
cetuximab none         L01X C06
rituximab none         L01X C02
trastuzumab none         L01X C03
temozolomide insigni-
ficant
1 0 0 1 L01A X03
hydroxy-
carbamide
insigni-
ficant
3 3 0 0 L01X X05
pemetrexed insigni-
ficant
3
N.B.
3
N.B.
0 0 L01B A04
imatinib insigni-
ficant
5 3 0 2 L01X E01
cladribine insigni-
ficant
5
N.B.
3
N.B.
0 2 L01B B04
capecitabine insigni-
ficant
6 3 0 3 L01B C06
sunitnib insigni-
ficant
6
N.B.
3
N.B.
0 3 L01X E04
erlotinib insigni-
ficant
6
N.B.
3 0 3
N.B.
L01X E03
dasatinib insigni-
ficant
9
N.B.
3 0 3
N.B.
L01X E06
bortezomib insigni-
ficant
- - - 3 L01X X32
topotecan cannot be excl 1
N.B.
0 0 1
N.B.
L01X X17
busulfan cannot be excl 2
N.B.
0 0 2
N.B.
L01A B01
chlorambucil cannot be excl 2
N.B.
0 0 2
N.B.
L01A A02
melphalan cannot be excl 2
N.B.
0 0 2
N.B.
L01A A03
mercaptopurine cannot be excl 4
N.B.
3 0 1
N.B.
L01B B02
cyclophos-
phamide
cannot be excl 5 3 0 2 L01A A01
tioguanine cannot be excl 6 3 0 3 L01B B03
ifosfamide cannot be excl 6
N.B.
3 0 3
N.B.
L01A A06
methyl aminolevulinate cannot be excl 6
N.B.
3 0 3
N.B.
L01X D03
docetaxel cannot be excl 9
N.B.
3 3
N.B.
3 L01C D02
amsacrine cannot be excl - - - - L01X X01
anagrelide cannot be excl - - - - L01X X35
bleomycin cannot be excl - - - - L01D C01
clofarabine cannot be excl - - - - L01B B06
daunorubicin cannot be excl - - - - L01D B02
estramustine cannot be excl - - - - L01X X11
idarubicin cannot be excl - - - - L01D B06
miltefosine cannot be excl - - - - L01X X09
Endocrine therapy L02
triptorelin none         L02A E04
anastrozole insigni-
ficant
5 3 0 2 749 526  L02B G03
tamoxifen   9 3 3 3 892 541  L02B A01
bicalutamide cannot be excl - - - - 1 013 425  L02B B03
buserelin none         L02A E01
leuprorelin none         L02A E02
letrozole insigni-
ficant
4 3 0 1 215 190  L02B G04
estradiol high 9 3 3 3 5 553 012
C 3 066 259 
L02A A02
G03C A03
G03F A01
G03F A12
G03F A15
G03F A16
G03F A17
G03F B05
G03F B06
G03F B09
G03F B11
flutamide cannot be excl - - 3 - 35 770  L02B B01
medroxy-
progesterone
cannot be excl - - - - 1 764 361
C 993 867 
L02A B02
G03F A12
G03D A02
G03F B06
G03A C06
megestrol   9 3 3 3 L02A B01
Immunostimulants L03
filgrastim none         L03A A02
glatiramer none         L03A X13
interferon none         L03A B01
L03A B03
L03A B05
L03A B07
L03A B08
L03A B09
lenograstim none         L03A A10
pegfilgrastim none         L03A A13
tasonermin none         L03A X11
Immunosuppressive agents L04
azathioprine cannot be excl - - - - 605 256  L04A X01
methotrexate cannot be excl - - - - 1 798 897  L01B A01
abatacept none         L04A A24
adalimumab none         L04A A17
anakinra none         L04A C03
basiliximab none         L04A C02
certolizumab pegol none         L04A B05
daclizumab none         L04A C01
eculizumab none         L04A A25
efalizumab none         L04A A21
etanercept none         L04A B01
immunoglobulin none         J06B A01
J06B A02
J06B B01
L04A A04
infliximab none         L04A B02
muromonab none         25  L04A A02
ciclosporine insigni-
ficant
4 0 3 1 118 357  L04A D01
everolimus insigni-
ficant
8 3 3 2 4 442  L04A A18
leflunomide   8 3 3 2 51 970  L04A A13
mycophenolate Mofetil moderate 6 3 0 3 110 967  L04A A06